Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses — Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015

Petersen, Brett W.; Harms, Tiara; Reynolds, Mary G.; Harrison, Lee H.

doi:10.15585/mmwr.mm6510a2

Cited by 108 publications

(122 citation statements)

References 11 publications

(12 reference statements)

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Кроме того, периодическая вакцинация необходима для представителей определенных профессий (ученые, изучающие патогенные ортопоксвирусы, медицинские работники и др.) (Petersen et al, 2016). Разработка вакцин на основе высокоаттенуированных вирусов осповакцины, не способных размножаться в клетках человека (Meyer et al, 1991), привела к получению вакцин MVA и LC16m8 (Meyer et al, 1991; Kidokoro et al 2005), которые крайне редко вызывают побочные реакции и могут применяться даже для вакцинации индивидуумов с ослабленным иммунитетом (Olson, Shchelkunov, 2017).…”

Section: Discussionunclassified

Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice

et al. 2019

View full text Add to dashboard Cite

Despite the elimination of smallpox, orthopoxviruses continue to be a source of biological danger for humans, as cowpox and monkey pox viruses circulate in nature and the last virus can cause both sporadic cases of human diseases and outbreaks of smallpox-like infection. In addition, periodic vaccination is necessary for representatives of some professions (scientists studying pathogenic orthopoxviruses, medical personnel, etc.). Vaccination against smallpox virus with live vaccinia virus, which was widely used during the elimination of smallpox, induces the formation of long-term immunity in vaccinated people. However, providing a high level of protection, the vaccination is often accompanied by serious post-vaccination complications, the probability of which is particularly great for individuals with compromised immunity. In this regard, the development of preparations for the prevention and treatment of infections caused by orthopoxviruses remains important today. The aim of this study was to assess the immunogenicity in the mouse model of recombinant protein р35Δ12, designed previously on the base of the cowpox virus protein p35. It was previously shown that the protein р35Δ12 was recognized by fully human neutralizing anti-orthopoxviral antibody with high affinity. In this work, recombinant protein р35Δ12 produced in E. coli cells XL1-blue and purified by chromatography was used for two-time immunization of mice. Two weeks after the second immunization, blood samples were taken from mice and serum antibodies were analyzed. It was shown by ELISA and Western-blot analysis that immunized mice sera contained IgG antibodies specific to recombinant protein р35Δ12. Confocal microscopy showed that antibodies induced by the р35Δ12 protein were able to recognize Vero E6 cells infected with the LIVP-GFP vaccinia virus. In addition, the antibodies in the serum of immunized mice were able to neutralize the infectivity of the vaccinia virus LIVP-GFP in the plaque reduction neutralization test in vitro. These experiments have demonstrated promising properties of the р35Δ12 protein if it were used as a component of vaccine for prophylaxis of orthopoxvirus infections.

show abstract

Section: Discussionunclassified

Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…These options should be reserved for very severe disease courses and personal at high risk of infection. The use of antiviral drugs in human cowpox is off-label [26,27].…”

Section: Discussionmentioning

confidence: 99%

Cowpox virus infection from pet rat

Wollina¹,

Hansel²,

Schönlebe³

2018

Our Dermatol Online

View full text Add to dashboard Cite

“…In the United States, the second-generation smallpox vaccine ACAM2000 has been licensed by the Food and Drug Administration (FDA) and purchased for the Strategic National Stockpile (SNS) to be used during an emergency involving smallpox. Vaccination with ACAM2000 is also recommended for select laboratory and healthcare personnel (Petersen et al, 2015b). …”

Section: Vaccination Of Healthcare Workersmentioning

confidence: 99%

Vaccinating against monkeypox in the Democratic Republic of the Congo

et al. 2019

Self Cite

View full text Add to dashboard Cite

Healthcare-associated transmission of monkeypox has been observed on multiple occasions in areas where the disease is endemic. Data collected by the US Centers for Disease Control and Prevention (CDC) from an ongoing CDC-supported program of enhanced surveillance in the Tshuapa Province of the Democratic Republic of the Congo, where the annual incidence of human monkeypox is estimated to be 3.5–5/10,000, suggests that there is approximately one healthcare worker infection for every 100 confirmed monkeypox cases. Herein, we describe a study that commenced in February 2017, the intent of which is to evaluate the effectiveness, immunogenicity, and safety of a third-generation smallpox vaccine, IMVAMUNE®, in healthcare personnel at risk of monkeypox virus (MPXV) infection. We describe procedures for documenting exposures to monkeypox virus infection in study participants, and outline lessons learned that may be of relevance for studies of other investigational medical countermeasures in hard to reach, under-resourced populations.

show abstract

Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses — Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015

Cited by 108 publications

References 11 publications

Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice

Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice

Cowpox virus infection from pet rat

Vaccinating against monkeypox in the Democratic Republic of the Congo

Contact Info

Product

Resources

About